Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
39
SLNCF Quote, Financials, Valuation and Earnings
Last price:
$1.60
Seasonality move
:
18.36%
Day range:
$1.60 - $1.60
52-week range:
$0.50 - $2.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
112.71x
P/B ratio:
3.06x
Volume:
--
Avg. volume:
172
1-year change:
6.67%
Market cap:
$226.7M
Revenue:
$43.3M
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
|
AUTL
Autolus Therapeutics Plc
|
$24.4M | -$0.42 | 201.73% | -6.42% | $9.32 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SLNCF
Silence Therapeutics Plc
|
$1.60 | -- | $226.7M | -- | $0.00 | 0% | 112.71x |
|
AUTL
Autolus Therapeutics Plc
|
$1.43 | $9.32 | $380.6M | -- | $0.00 | 0% | 7.43x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.21 | $17.94 | $1M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.19 | $104.00 | $9.1M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$11.34 | -- | $1.4B | -- | $0.00 | 0% | 6.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.622 | 0.09% | 5.88x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.023 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.482 | 0.95% | 4.03x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.408 | -- | 1.99x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
Silence Therapeutics Plc vs. Competitors
-
Which has Higher Returns SLNCF or AUTL?
Autolus Therapeutics Plc has a net margin of -13181.13% compared to Silence Therapeutics Plc's net margin of -373.3%. Silence Therapeutics Plc's return on equity of -101.79% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About SLNCF or AUTL?
Silence Therapeutics Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.32 which suggests that it could grow by 551.9%. Given that Autolus Therapeutics Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNCFSilence Therapeutics Plc1 0 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is SLNCF or AUTL More Risky?
Silence Therapeutics Plc has a beta of 0.776, which suggesting that the stock is 22.438% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.946%.
-
Which is a Better Dividend Stock SLNCF or AUTL?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNCF or AUTL?
Silence Therapeutics Plc quarterly revenues are $159K, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Silence Therapeutics Plc's net income of -$21M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 112.71x versus 7.43x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M AUTLAutolus Therapeutics Plc7.43x -- $21.1M -$78.6M
-
Which has Higher Returns SLNCF or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -13181.13% compared to Silence Therapeutics Plc's net margin of --. Silence Therapeutics Plc's return on equity of -101.79% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About SLNCF or BDRX?
Silence Therapeutics Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 14598.46%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNCFSilence Therapeutics Plc1 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is SLNCF or BDRX More Risky?
Silence Therapeutics Plc has a beta of 0.776, which suggesting that the stock is 22.438% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock SLNCF or BDRX?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNCF or BDRX?
Silence Therapeutics Plc quarterly revenues are $159K, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$21M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 112.71x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns SLNCF or NCNA?
NuCana Plc has a net margin of -13181.13% compared to Silence Therapeutics Plc's net margin of --. Silence Therapeutics Plc's return on equity of -101.79% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About SLNCF or NCNA?
Silence Therapeutics Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 949671.69%. Given that NuCana Plc has higher upside potential than Silence Therapeutics Plc, analysts believe NuCana Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNCFSilence Therapeutics Plc1 0 0 NCNANuCana Plc0 1 0 -
Is SLNCF or NCNA More Risky?
Silence Therapeutics Plc has a beta of 0.776, which suggesting that the stock is 22.438% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.66%.
-
Which is a Better Dividend Stock SLNCF or NCNA?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNCF or NCNA?
Silence Therapeutics Plc quarterly revenues are $159K, which are larger than NuCana Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$21M is lower than NuCana Plc's net income of -$378.9K. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 112.71x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns SLNCF or OXBDF?
Oxford Biomedica Plc has a net margin of -13181.13% compared to Silence Therapeutics Plc's net margin of --. Silence Therapeutics Plc's return on equity of -101.79% beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About SLNCF or OXBDF?
Silence Therapeutics Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Silence Therapeutics Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Silence Therapeutics Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings SLNCFSilence Therapeutics Plc1 0 0 OXBDFOxford Biomedica Plc0 0 0 -
Is SLNCF or OXBDF More Risky?
Silence Therapeutics Plc has a beta of 0.776, which suggesting that the stock is 22.438% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.226%.
-
Which is a Better Dividend Stock SLNCF or OXBDF?
Silence Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Silence Therapeutics Plc pays -- of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SLNCF or OXBDF?
Silence Therapeutics Plc quarterly revenues are $159K, which are larger than Oxford Biomedica Plc quarterly revenues of --. Silence Therapeutics Plc's net income of -$21M is higher than Oxford Biomedica Plc's net income of --. Notably, Silence Therapeutics Plc's price-to-earnings ratio is -- while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Silence Therapeutics Plc is 112.71x versus 6.15x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M OXBDFOxford Biomedica Plc6.15x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
